The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Molecular subtypes, body mass index (BMI), and their time-varying prognostic impact in node-positive breast cancer (BC): Pooled analysis from the WSG AM-01 and -02 trials.
O. Gluz
Honoraria - Sanofi
C. Liedtke
Honoraria - Sanofi
R. E. Kates
No relevant relationships to disclose
J. B. Huober
Consultant or Advisory Role - Amgen; Sanofi
Honoraria - Sanofi
S. Mohrmann
No relevant relationships to disclose
A. Hartmann
No relevant relationships to disclose
C. Thomssen
Consultant or Advisory Role - Sanofi
Honoraria - Amgen; Sanofi
V. Moebus
Honoraria - Amgen
Research Funding - Amgen
U. Nitz
Consultant or Advisory Role - Sanofi
Honoraria - Amgen; Sanofi
Research Funding - Amgen; Sanofi
N. Harbeck
Consultant or Advisory Role - Sanofi
Honoraria - Amgen; Sanofi
Research Funding - Sanofi